Pfizer Inc. reported stronger-than-expected Q4 and full-year 2025 results, returning $9.8 billion to shareholders. The pharmaceutical giant is navigating a pivotal transition, leveraging recent acquisitions and a promising obesity drug pipeline to offset upcoming patent expirations and drive growth beyond 2028.
While Eli Lilly's stock has cooled in 2026 after a historic rally, Wall Street analysts remain overwhelmingly bullish, betting the pharmaceutical giant's blockbuster obesity treatments will drive long-term growth.
A growing movement, led by AARP, aims to eliminate state taxes on Social Security benefits in the handful of states that still impose them. While promising more disposable income for retirees, analyses suggest the windfalls could disproportionately benefit higher-income households.
Arm Holdings PLC (ARM) shares gained nearly 2% in a session marked by subdued options trading. While call buying outpaced puts, a steepening put-call skew points to heightened investor caution as the chip designer approaches its next earnings report.
The race for public capital intensifies in the tech and space sectors. OpenAI reportedly fast-tracks its IPO to Q4 amid fierce competition with Anthropic, while York Space Systems and Ethos successfully launch their first trading days, signaling a robust start for new listings.
As demand for AI compute power surges, infrastructure providers Applied Digital and CoreWeave are posting explosive growth. But behind the soaring revenues lie starkly different financial profiles and risks, forcing investors to look beyond the hype.
Blackstone President Jon Gray warns that AI-driven disruption is a paramount concern for the $1.27 trillion asset manager, urging a focus on infrastructure investments as the safest play in the transformative trend.
CNBC's Jim Cramer has issued a bullish call on Vail Resorts (NYSE: MTN), recommending investors buy the stock after a significant decline, citing confidence in the company's management and long-term prospects in the luxury resort and ski industry.
Financial expert Suze Orman highlights a pervasive spending habit that is quietly consuming a quarter of the average retiree's Social Security income. As savings rates plummet and retail spending climbs, her advice to reclassify 'wants' as 'needs' strikes at the heart of a growing financial discipline crisis.
New forecasts project Google's Pixel line to significantly outpace a slowing global smartphone market in 2026, fueled by AI features and international expansion, while component shortages squeeze competitors.
CNBC's Jim Cramer has pointed to Brinker International, parent company of Chili's and Maggiano's, as a potential buying opportunity following a quarterly earnings report that significantly exceeded analyst expectations.
CNBC's Jim Cramer reaffirmed his confidence in AutoZone (AZO) during a recent 'Mad Money' segment, addressing investor concerns by highlighting the auto parts retailer's robust cash generation and operational strength.
CNBC's Jim Cramer suggests Roper Technologies' stock performance is unlikely to see a sustained turnaround until investor sentiment toward software stocks improves, despite the company's diverse portfolio of niche applications.
CNBC's Jim Cramer expressed bewilderment over the market's reaction to payroll giant ADP's latest earnings, suggesting a pessimistic narrative may be overshadowing the company's fundamentals.
CNBC's Jim Cramer suggests United Rentals' recent 13% stock plunge following weak earnings may not spell doom for the equipment rental giant, framing it as a potential indicator for the wider industrial economy.
CNBC's Jim Cramer has turned bullish on logistics giant C.H. Robinson, pointing to recent positive signals in the freight sector as a key catalyst for the stock's potential.
Food distribution giant Sysco saw shares jump nearly 11% after reporting better-than-expected quarterly results, prompting CNBC's Jim Cramer to highlight the stock as undervalued amid a broader market rally.
CNBC's Jim Cramer pointed to Texas Instruments as a notable standout following its latest earnings, praising its guidance while the broader chip sector sees significant momentum.
CNBC's Jim Cramer voiced strong support for AstraZeneca when questioned by an investor considering a switch to AbbVie, highlighting the resilience of the pharmaceutical giant's oncology division.
Darden Restaurants is shuttering half of its remaining Bahama Breeze outlets and converting the rest to other brands, marking the near-end of the 28-year-old Caribbean-themed concept.
